Cell & Gene: The Podcast

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris sits down with Peter Altman, Ph.D., CEO of BioCardia, to discuss the company’s evolution from a cardiac biotherapeutic delivery firm to a developer of autologous and allogeneic cell therapies for cardiovascular and pulmonary diseases. Altman highlights BioCardia’s CardiAMP program, a precision medicine approach that pre-screens patients based on their cell profiles to improve trial outcomes and reduce costs. He explains why no cardiac cell therapy has yet received FDA approval, citing challenges in delivery, immune rejection, and arrhythmia risks. Altman outlines BioCardia’s near-term roadmap, including regulatory submissions in the U.S. and Japan and the launch of a second trial focused on patients most likely to benefit.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.In this episode of the Cell & Gene podcast, Host Erin Harris speaks with Alicia Zhou, Ph.D., CEO of the Cancer Research Institute (CRI), about CRI’s mission to advance cancer immunotherapy and the critical role of federal funding, particularly from the NIH, in supporting basic and translational cancer research. Dr. Zhou highlights CRI’s focus on funding early-stage science and clinical trials to move immunotherapy toward curing all cancers. She covers the serious implications of recent U.S. Government funding cuts, including NIH budget freezes and halted grant review processes, which are already impacting biomedical research institutions, graduate programs, and clinical trials. In light of the NIH budget cuts, Dr. Zhou explains how CRI is stepping up by committing an additional $2.5 million from its reserves to fund 10 postdoctoral fellowships.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.On the 100th episode of Cell & Gene: The Podcast, Host, Erin Harris, sits down with Audrey Greenberg, Founder and CEO of AG Capital Advisors. Audrey is the award-winning executive, board director, and strategic advisor with a proven track record of launching, scaling, and successfully exiting multi-billion-dollar ventures. They explore the biggest challenges and opportunities facing CGT biotech leaders today; the funding crisis in biotech, the evolving investment landscape, and whether the traditional VC-driven model is still sustainable. They also examine what it really takes to scale a biotech company from startup to market leader, the role of AI-driven drug discovery, and how big tech’s growing influence could reshape the industry. You'll hear their discussion on leadership challenges in biotech, the need for more diverse voices at the top, and what must change to empower the next generation of women leaders in CGT, and more.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.In this episode of Cell & Gene: The Podcast, Host Erin Harris dives into the world of retinal gene therapy with Kenji Fujita, M.D., Chief Medical Officer of Atsena Therapeutics. Atsena develops treatments for inherited retinal diseases, including X-linked retinoschisis (XLRS), a rare genetic condition that currently has no FDA-approved therapy. They talk through the impact of XLRS on patients, the challenges of gene delivery to the retina, and how Atsena’s AAV vector technology is designed to overcome these hurdles. They also discuss the significance of the Fast Track designation recently granted to Atsena’s XLRS program, the role of patient advocacy in rare disease research, and the key milestones to watch for in the months ahead.Subscribe to the podcast!Apple | Spotify | YouTube

We love to hear from our listeners. Send us a message.In this episode, Host Erin Harris sits down with Dr. Simrit Parmar, Founder of Cellenkos, to explore how the company is pioneering umbilical cord blood-derived Regulatory T cell (Treg) cell therapies for autoimmune and inflammatory diseases. Dr. Parmar shares the vision behind Cellenkos, the advantages of cord blood-derived Tregs over other sources, and how their CRANE technology platform enhances precision in targeting diseases. They also discuss key findings from their Phase 1b trial for CK0804, the challenges of scaling up off-the-shelf Treg therapies, and what’s next for Cellenkos in 2025.Subscribe to the podcast!Apple | Spotify | YouTube

Omkar Kawalekar, Ph.D., a Senior Manager and NextGen Therapies Manufacturing & Supply Chain Lead at Deloitte Consulting, dives into the future of cell and gene therapy manufacturing. He discusses how distributed manufacturing models can tackle capacity issues and supply chain threats. Omkar emphasizes the role of automation in minimizing variability between batches and the significance of digital technologies in optimizing production. He explores vital decisions for CGT companies regarding in-house versus CDMO partnerships, providing insights on efficiency and innovation.

We love to hear from our listeners. Send us a message.In this episode, Erin Harris sits down with Faraz Ali, CEO of Tenaya Therapeutics, to explore the cutting-edge world of gene therapies for heart diseases. As Tenaya makes significant strides in developing innovative treatments, Ali shares insights on Tenaya's gene therapy platform, their in-house manufacturing capabilities, and the potential impact of their therapies on prevalent heart conditions. They also discuss the complexities of commercializing gene therapies, industry-wide developments, and Tenaya's roadmap for 2025. This conversation offers a unique glimpse into the future of cardiac care and the transformative potential of gene therapies in treating heart diseases.Subscribe to the podcast!Apple | Spotify | YouTube

Helen Sabzevari, Ph.D., President and CEO of Precigen, shares insights on innovative adenovirus-based therapies. She discusses the promising use of gorilla adenovectors, which enhance the delivery of large genetic payloads for effective gene therapies. Sabzevari reveals exciting results from Precigen's recent BLA submission, with over 50% of patients achieving Complete Response in pivotal studies. She also highlights the company's groundbreaking work in treating recurrent respiratory papillomatosis and the potential for broad applications in immuno-oncology and beyond.

We love to hear from our listeners. Send us a message.Christopher Horan, Chief Technical Operations Officer, Artiva Biotherapeutics joins Cell & Gene: The Podcast Host, Erin Harris, to discuss the advantages natural killer (NK) cells have offer over T cells in terms of safety and efficacy for autoimmune disease. They take a deep dive into the key factors that make NK cells promising for ‘off-the-shelf’ cell therapy products. They cover Artiva's "manufacturing first" approach to enabling scalable NK cell production, and much more.Subscribe to the podcast!Apple | Spotify | YouTube

Christopher Choi, Ph.D., is an expert in cell and gene therapy manufacturing and the Director of the GMP Facility at Roswell Park Comprehensive Cancer Center. In this discussion, he reveals plans for a new Cell and Gene Therapy Hub set to open in 2025, aimed at advancing cancer treatment. Choi emphasizes the critical role of automation in manufacturing and shares valuable advice for emerging biotech firms on quality management, project coordination, and the importance of a quality by design approach to improve market readiness.